Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
 Back to Details

Connection

Ruud Dings to Humans

This is a "connection" page, showing publications Ruud Dings has written about Humans.

 
Connection Strength
  
 
 
0.477
  
  1. Jenkins SV, Shah S, Jamshidi-Parsian A, Mortazavi A, Kristian H, Boysen G, Vang KB, Griffin RJ, Rajaram N, Dings RPM. Acquired Radiation Resistance Induces Thiol-dependent Cisplatin Cross-resistance. Radiat Res. 2024 02 01; 201(2):174-187.
    View in: PubMed
    Score: 0.036
  2. Dings RPM, Miller MC, Griffin RJ, Mayo KH. Galectins as Molecular Targets for Therapeutic Intervention. Int J Mol Sci. 2018 Mar 19; 19(3).
    View in: PubMed
    Score: 0.024
  3. Dings RP, Kumar N, Miller MC, Loren M, Rangwala H, Hoye TR, Mayo KH. Structure-based optimization of angiostatic agent 6DBF7, an allosteric antagonist of galectin-1. J Pharmacol Exp Ther. 2013 Mar; 344(3):589-99.
    View in: PubMed
    Score: 0.017
  4. Dings RP, Miller MC, Nesmelova I, Astorgues-Xerri L, Kumar N, Serova M, Chen X, Raymond E, Hoye TR, Mayo KH. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J Med Chem. 2012 Jun 14; 55(11):5121-9.
    View in: PubMed
    Score: 0.016
  5. Dings RP, Haseman JR, Mayo KH. Probing structure-activity relationships in bactericidal peptide betapep-25. Biochem J. 2008 Aug 15; 414(1):143-50.
    View in: PubMed
    Score: 0.012
  6. Dings RP, Van Laar ES, Webber J, Zhang Y, Griffin RJ, Waters SJ, MacDonald JR, Mayo KH. Ovarian tumor growth regression using a combination of vascular targeting agents anginex or topomimetic 0118 and the chemotherapeutic irofulven. Cancer Lett. 2008 Jul 08; 265(2):270-80.
    View in: PubMed
    Score: 0.012
  7. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  8. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  9. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  10. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  11. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  12. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  13. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  14. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  15. Sonderman KA, Wolf LL, Armstrong LB, Taylor K, Jiang W, Weil BR, Koehlmoos TP, Ricca RL, Weldon CB, Haider AH, Rice-Townsend SE. Testicular atrophy following inguinal hernia repair in children. Pediatr Surg Int. 2018 May; 34(5):553-560.
    View in: PubMed
    Score: 0.012
  16. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo KH, Griffin RJ. Scheduling of radiation with angiogenesis inhibitors anginex and Avastin improves therapeutic outcome via vessel normalization. Clin Cancer Res. 2007 Jun 01; 13(11):3395-402.
    View in: PubMed
    Score: 0.011
  17. Griffin RJ, Molema G, Dings RP. Angiogenesis treatment, new concepts on the horizon. Angiogenesis. 2006; 9(2):67-72.
    View in: PubMed
    Score: 0.011
  18. Dings RP, Chen X, Hellebrekers DM, van Eijk LI, Zhang Y, Hoye TR, Griffioen AW, Mayo KH. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J Natl Cancer Inst. 2006 Jul 05; 98(13):932-6.
    View in: PubMed
    Score: 0.011
  19. Dings RP, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer. 2005 Jun 10; 115(2):312-9.
    View in: PubMed
    Score: 0.010
  20. Jamshidi-Parsian A, Jenkins SV, Tran A, Bragg A, Davis R, Griffin C, Siegel E, Dings RPM, Griffin RJ, Boysen G. CB-839 induces reversible dormancy in lung tumor-cells. Eur J Pharmacol. 2024 Nov 05; 982:176912.
    View in: PubMed
    Score: 0.009
  21. Ippel H, Miller MC, Dings RPM, Ludwig AK, Gabius HJ, Mayo KH. Cysteine Oxidation in Human Galectin-1 Occurs Sequentially via a Folded Intermediate to a Fully Oxidized Unfolded Form. Int J Mol Sci. 2024 Jun 25; 25(13).
    View in: PubMed
    Score: 0.009
  22. Dings RP, van der Schaft DW, Hargittai B, Haseman J, Griffioen AW, Mayo KH. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 2003 May 08; 194(1):55-66.
    View in: PubMed
    Score: 0.009
  23. Dings RP, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 2003 Jan 15; 63(2):382-5.
    View in: PubMed
    Score: 0.008
  24. Dings RP, Nesmelova I, Griffioen AW, Mayo KH. Discovery and development of anti-angiogenic peptides: A structural link. Angiogenesis. 2003; 6(2):83-91.
    View in: PubMed
    Score: 0.008
  25. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  26. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  27. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  28. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  29. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  30. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  31. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  32. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  33. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  34. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  35. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  36. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  37. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  38. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  39. McGoogan KE, Haafiz AB, Gonz?lez Peralta RP. Herpes simplex virus hepatitis in infants: clinical outcomes and correlates of disease severity. J Pediatr. 2011 Oct; 159(4):608-11.
    View in: PubMed
    Score: 0.007
  40. Boysen G, Jamshidi-Parsian A, Davis MA, Siegel ER, Simecka CM, Kore RA, Dings RPM, Griffin RJ. Glutaminase inhibitor CB-839 increases radiation sensitivity of lung tumor cells and human lung tumor xenografts in mice. Int J Radiat Biol. 2019 04; 95(4):436-442.
    View in: PubMed
    Score: 0.006
  41. Nowak-Sliwinska P, Alitalo K, Allen E, Anisimov A, Aplin AC, Auerbach R, Augustin HG, Bates DO, van Beijnum JR, Bender RHF, Bergers G, Bikfalvi A, Bischoff J, B?ck BC, Brooks PC, Bussolino F, Cakir B, Carmeliet P, Castranova D, Cimpean AM, Cleaver O, Coukos G, Davis GE, De Palma M, Dimberg A, Dings RPM, Djonov V, Dudley AC, Dufton NP, Fendt SM, Ferrara N, Fruttiger M, Fukumura D, Ghesqui?re B, Gong Y, Griffin RJ, Harris AL, Hughes CCW, Hultgren NW, Iruela-Arispe ML, Irving M, Jain RK, Kalluri R, Kalucka J, Kerbel RS, Kitajewski J, Klaassen I, Kleinmann HK, Koolwijk P, Kuczynski E, Kwak BR, Marien K, Melero-Martin JM, Munn LL, Nicosia RF, Noel A, Nurro J, Olsson AK, Petrova TV, Pietras K, Pili R, Pollard JW, Post MJ, Quax PHA, Rabinovich GA, Raica M, Randi AM, Ribatti D, Ruegg C, Schlingemann RO, Schulte-Merker S, Smith LEH, Song JW, Stacker SA, Stalin J, Stratman AN, Van de Velde M, van Hinsbergh VWM, Vermeulen PB, Waltenberger J, Weinstein BM, Xin H, Yetkin-Arik B, Yla-Herttuala S, Yoder MC, Griffioen AW. Consensus guidelines for the use and interpretation of angiogenesis assays. Angiogenesis. 2018 08; 21(3):425-532.
    View in: PubMed
    Score: 0.006
  42. Lee DE, Alhallak K, Jenkins SV, Vargas I, Greene NP, Quinn KP, Griffin RJ, Dings RPM, Rajaram N. A Radiosensitizing Inhibitor of HIF-1 alters the Optical Redox State of Human Lung Cancer Cells In Vitro. Sci Rep. 2018 06 11; 8(1):8815.
    View in: PubMed
    Score: 0.006
  43. Griffin RJ, Dings RPM, Makhoul I. Further rationale for optimal combined modality treatments. Oncotarget. 2017 04 18; 8(16):25831-25832.
    View in: PubMed
    Score: 0.006
  44. L?ppchen T, Dings RP, Rossin R, Simon JF, Visser TJ, Bakker M, Walhe P, van Mourik T, Donato K, van Beijnum JR, Griffioen AW, Lub J, Robillard MS, Mayo KH, Gr?ll H. Novel analogs of antitumor agent calixarene 0118: Synthesis, cytotoxicity, click labeling with 2-[(18)F]fluoroethylazide, and in vivo evaluation. Eur J Med Chem. 2015 Jan 07; 89:279-95.
    View in: PubMed
    Score: 0.005
  45. Saarinen NM, W?rri A, Dings RP, Airio M, Smeds AI, M?kel? S. Dietary lariciresinol attenuates mammary tumor growth and reduces blood vessel density in human MCF-7 breast cancer xenografts and carcinogen-induced mammary tumors in rats. Int J Cancer. 2008 Sep 01; 123(5):1196-204.
    View in: PubMed
    Score: 0.003
  46. Hellebrekers DM, Castermans K, Vir? E, Dings RP, Hoebers NT, Mayo KH, Oude Egbrink MG, Molema G, Fuks F, van Engeland M, Griffioen AW. Epigenetic regulation of tumor endothelial cell anergy: silencing of intercellular adhesion molecule-1 by histone modifications. Cancer Res. 2006 Nov 15; 66(22):10770-7.
    View in: PubMed
    Score: 0.003
  47. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci U S A. 2006 Oct 24; 103(43):15975-80.
    View in: PubMed
    Score: 0.003
  48. Brandwijk RJ, Dings RP, van der Linden E, Mayo KH, Thijssen VL, Griffioen AW. Anti-angiogenesis and anti-tumor activity of recombinant anginex. Biochem Biophys Res Commun. 2006 Oct 27; 349(3):1073-8.
    View in: PubMed
    Score: 0.003
  49. van Beijnum JR, Dings RP, van der Linden E, Zwaans BM, Ramaekers FC, Mayo KH, Griffioen AW. Gene expression of tumor angiogenesis dissected: specific targeting of colon cancer angiogenic vasculature. Blood. 2006 Oct 01; 108(7):2339-48.
    View in: PubMed
    Score: 0.003
  50. Dirkx AE, oude Egbrink MG, Castermans K, van der Schaft DW, Thijssen VL, Dings RP, Kwee L, Mayo KH, Wagstaff J, Bouma-ter Steege JC, Griffioen AW. Anti-angiogenesis therapy can overcome endothelial cell anergy and promote leukocyte-endothelium interactions and infiltration in tumors. FASEB J. 2006 Apr; 20(6):621-30.
    View in: PubMed
    Score: 0.003
  51. Brandwijk RJ, Nesmelova I, Dings RP, Mayo KH, Thijssen VL, Griffioen AW. Cloning an artificial gene encoding angiostatic anginex: From designed peptide to functional recombinant protein. Biochem Biophys Res Commun. 2005 Aug 12; 333(4):1261-8.
    View in: PubMed
    Score: 0.002
  52. Thijssen VL, Brandwijk RJ, Dings RP, Griffioen AW. Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res. 2004 Oct 01; 299(2):286-93.
    View in: PubMed
    Score: 0.002
  53. Wild R, Dings RP, Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: Potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer. 2004 Jun 20; 110(3):343-51.
    View in: PubMed
    Score: 0.002
  54. Wild R, Yokoyama Y, Dings RP, Ramakrishnan S. VEGF-DT385 toxin conjugate inhibits mammary adenocarcinoma development in a transgenic mouse model of spontaneous tumorigenesis. Breast Cancer Res Treat. 2004 May; 85(2):161-71.
    View in: PubMed
    Score: 0.002
  55. Tromp SC, oude Egbrink MG, Dings RP, van Velzen S, Slaaf DW, Hillen HF, Tangelder GJ, Reneman RS, Griffioen AW. Tumor angiogenesis factors reduce leukocyte adhesion in vivo. Int Immunol. 2000 May; 12(5):671-6.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.